BeiGene Ltd
(HKSE:06160)
HK$
129.8
-4 (-2.99%)
Market Cap: 186.24 Bil
Enterprise Value: 180.29 Bil
PE Ratio: 0
PB Ratio: 6.72
GF Score: 83/100 Beigene Ltd to Discuss Final Results of the ALPINE Trial Late-Breaker Presentation Transcript
Dec 13, 2022 / 08:00PM GMT
Release Date Price:
HK$124.5
(+2.64%)
Operator
Presentation
Dec 13, 2022 / 08:00PM GMT
=====================
Corporate Participants
=====================
* John V. Oyler
BeiGene, Ltd. - Co-Founder, Executive Chairman & CEO
* Josh Neiman
BeiGene, Ltd. - Senior VP, Chief Commercial Officer of North America & Europe
* Kevin C. Mannix
BeiGene, Ltd. - SVP of IR.
* Mehrdad Mobasher
BeiGene, Ltd. - Chief Medical Officer of Hematology
=====================
Conference Call Participants
=====================
* Andrew Scott Berens
SVB Securities LLC, Research Division - Senior MD of Medical Supplies and Devices & Senior Research Analyst
* Jennifer Brown
* Mazyar Shadman
=====================
Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot